Cas:16796-52-4 3-Bromobenzamidine hydrochloride manufacturer & supplier

We serve Chemical Name:3-Bromobenzamidine hydrochloride CAS:16796-52-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Bromobenzamidine hydrochloride

Chemical Name:3-Bromobenzamidine hydrochloride
CAS.NO:16796-52-4
Synonyms:3-Bromobenzamidine hydrochloride;3-Bromobenzimidamide,HCl;3-Bromobenzimidamide, HCl;Benzenecarboximidamide, 3-bromo-, hydrochloride (1:1);3-Bromobenzenecarboximidamide hydrochloride (1:1)
Molecular Formula:C7H8BrClN2
Molecular Weight:235.509
HS Code:2925290090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:307.3ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:49.87000
Exact Mass:233.955933
LogP:3.33520

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-Bromobenzamidine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromobenzenecarboximidamide hydrochloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenecarboximidamide, 3-bromo-, hydrochloride (1:1) Use and application,3-Bromobenzamidine hydrochloride technical grade,usp/ep/jp grade.


Related News: The pivotal TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) phase III programme includes two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of anifrolumab versus placebo. Dehydrosimvastatin manufacturers The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. [1,3]Dioxolo[4,5-b]pyridin-7-amine suppliers Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. (2E)-3-[4-(Trifluormethyl)phenyl]prop-2-enal vendor & factory.